Dermata Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | $4.8M | $4.3M | — | — | — |
| Research and development | $2.9M | $8.2M | $4.1M | $5.7M | $3.5M |
| Operating expenses | $7.8M | $12.5M | $8.0M | $9.7M | — |
| Operating income | -$7.8M | -$12.5M | -$8.0M | -$9.7M | -$7.9M |
| Interest expense | — | — | — | — | $45,613 |
| Income tax expense | — | $0 | $0 | $0 | $0 |
| Net income | -$7.6M | -$12.3M | -$7.8M | -$9.6M | -$7.9M |
| Balance Sheet | |||||
| Cash and equivalents | $7.5M | $3.2M | — | $6.2M | $10.8M |
| Current assets | — | — | — | — | $11.6M |
| Total assets | $7.9M | $3.5M | $8.0M | $6.9M | $11.6M |
| Current liabilities | — | — | — | — | $1.5M |
| Total liabilities | $1.6M | $2.0M | $1.6M | $922,634 | $1.5M |
| Stockholders' equity | $6.2M | $1.6M | $6.4M | $6.0M | $10.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.8M | -$11.2M | -$6.4M | -$8.8M | -$5.7M |
| Depreciation and amortization | — | — | — | — | $0 |
| Stock-based compensation | $143,732 | $657,649 | $522,082 | $930,325 | $1.9M |
Shares outstanding 4.0M
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.